Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical breakthrough

TESEO Trial Shortens Chagas Disease Treatment

Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 23, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The results could improve treatment adherence and expand access to Chagas disease therapy, potentially benefiting manufacturers of benznidazole and public health programs in endemic regions. However, the impact on major pharmaceutical markets is limited because Chagas is a neglected tropical disease with a small commercial footprint and phase 3 confirmation is still required.

pharmaceuticals healthcare

The TESEO trial, a phase 2b randomized clinical study co-led by the Barcelona Institute for Global Health (ISGlobal), the University of Texas at Austin (UTEP) and the Bolivian organization CEADES, found that a 30-day once-daily course of benznidazole is as effective as the current 60-day twice-daily standard for treating chronic Trypanosoma cruzi infection, the parasite that causes Chagas disease. Results were published in The Lancet on September 22, 2026. The trial enrolled 450 adults at three centers in Bolivia and compared six regimens: three benznidazole schedules (60-day standard, 30-day and 90-day) and three nifurtimox schedules. Only the 30-day benznidazole regimen significantly reduced side effects, with 37 percent of participants experiencing a drug-related adverse event versus 60 percent on the standard regimen, and 83 percent completing treatment without interruption versus 60 percent. Three years after treatment, the parasite remained undetectable in 94 percent of the 30-day group versus 95 percent in the standard group, meeting the prespecified non-inferiority criterion. The shorter course also uses a quarter of the drug, allowing four patients to be treated with the amount previously used for one. Nifurtimox regimens were less effective overall, with clearance rates of 81 to 90 percent. The trial was funded by the Norway — Norwegian Institute of Public Health, part of the United States — National Institutes of Health, with partial support from the United States — National Institute on Minority Health and Health Disparities and UTEP's Border Biomedical Research Center. Larger phase 3 trials are needed before the 30-day regimen can be incorporated into treatment guidelines. Chagas disease affects more than seven million people worldwide, mainly in Latin America, and is a growing public health concern in the United States, Europe and Japan.

50 CEADES co-led trial
ngo
Bolivian health organization that co-led the trial and provided clinical sites in Bolivia, strengthening its role in neglected disease research.
Importance 75.0 Sentiment 10.0
per
UTEP professor and co-senior author who led the trial's scientific effort and highlighted its head-to-head design.
Importance 70.0 Sentiment 5.0
per
ISGlobal co-senior author who emphasized the improved safety profile and potential to increase treatment completion.
Importance 65.0 Sentiment 5.0
per
CEADES co-senior author who noted the drug supply efficiency of the shorter regimen.
Importance 65.0 Sentiment 5.0
govactor
Funded the trial with an approximately $8 million award, supporting research into neglected tropical diseases.
Importance 55.0 Sentiment 5.0
cnt
Hosted the three trial centers where 450 adults were enrolled, reflecting the country's high Chagas disease burden.
Importance 50.0 Sentiment 5.0
govactor
Parent agency of the funding institutes, indirectly associated with the trial's support.
Importance 40.0 Sentiment 5.0
govactor
Partially supported the trial through award U54MD007592, contributing to health disparities research.
Importance 35.0 Sentiment 5.0
cnt
Chagas is a growing public health concern in the country, and US institutions and agencies played key roles in the trial.
Importance 30.0 Sentiment 5.0
per
UTEP College of Science dean who called the trial a landmark for the university.
Importance 25.0 Sentiment 5.0
per
Director of UTEP's Border Biomedical Research Center, which partially supported the trial.
Importance 20.0 Sentiment 5.0
per
Chair of UTEP's Department of Biological Sciences and BBRC co-director, commenting on the trial's significance.
Importance 20.0 Sentiment 5.0
cnt
Mentioned as a country where Chagas infection is an emerging public health concern.
Importance 15.0 Sentiment 5.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.